Sulfasalazine for newly diagnosed AML in older adults on chemo
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 trial studies whether sulfasalazine, added to intensive chemotherapy, can help older adults with newly diagnosed acute myeloid leukemia (AML). It aims to improve treatment effectiveness and track leukemia “leftover cells” in some participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 60 or older
- You have newly diagnosed AML (a short blood-count medicine like hydroxyurea and/or steroids before study is allowed)
- Your doctor feels you can safely receive intensive chemotherapy
- Your kidney and liver tests are good enough (and your blood tests are within allowed limits, unless explained by leukemia)
- Your general health is good enough (ECOG 0–2)
- You have no recent allergies or major medical issues listed for this specific study medicine and chemo
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.